External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients.
| Title: | External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients. |
|---|---|
| Authors: | He S; Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China; Department of Cardiology, National University Heart Centre, Singapore.; Wang Z; Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China; Department of Cardiology, National University Heart Centre, Singapore.; Cheem TH; Department of Cardiology, National University Heart Centre, Singapore.; Liao H; Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.; Chen X; Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: happensky@163.com.; He Y; Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: huaxiheyong@163.com. |
| Source: | The Canadian journal of cardiology [Can J Cardiol] 2019 Dec; Vol. 35 (12), pp. 1800-1806. Date of Electronic Publication: 2019 May 30. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Validation Study |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 8510280 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1916-7075 (Electronic) Linking ISSN: 0828282X NLM ISO Abbreviation: Can J Cardiol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Jan./Feb. 2011- : Oxford, UK : Elsevier; Original Publication: [Oakville, Ont. : Canadian Cardiology Publications Inc., c1984- |
| MeSH Terms: | Cardiomyopathy, Hypertrophic/*epidemiology ; Death, Sudden, Cardiac/*epidemiology ; Stroke/*epidemiology ; Thromboembolism/*epidemiology; Cardiomyopathy, Hypertrophic/diagnosis ; Cardiomyopathy, Hypertrophic/therapy ; Stroke/etiology ; Stroke/physiopathology ; Thromboembolism/etiology ; Thromboembolism/physiopathology ; Adult ; Female ; Follow-Up Studies ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Predictive Value of Tests ; Retrospective Studies ; Risk Assessment ; Severity of Illness Index ; Survival Analysis ; Tertiary Care Centers ; Time Factors |
| Abstract: | Background: Recently, a new risk model was developed, namely hypertrophic cardiomyopathy (HCM) risk for cerebrovascular accident, for estimating the risk of thromboembolism (TE) in patients with HCM. There is no study about the external validation of this model.; Methods: We evaluated the performance of the model for predicting TE in 417 patients with HCM recruited between 2008 and 2016, from a tertiary referral centre. The primary end point was 5-year TE, and the risk was calculated using the model formula.; Results: During a median follow-up of 3.5 years, 25 (6.0%) patients reached the TE end point, and 22 (5.3%) patients within the first 5 years. Within a 5-year time frame, the model showed a possibly helpful discrimination for TE (C-index for the whole cohort: 0.67, C-index for the subgroup without atrial fibrillation: 0.67) relative to its original C-index of 0.75. However, the calibration was not perfect, which suggested that there was an underestimation of 5-year TE risk in the whole cohort and different risk groups.; Conclusions: HCM risk for cerebrovascular accident demonstrated a possibly helpful discrimination for TE when applied in a new set of patients with HCM. However, the accurate estimation of absolute risk should be explored in future studies.; (Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.) |
| Comments: | Comment in: Can J Cardiol. 2019 Dec;35(12):1629-1630. doi: 10.1016/j.cjca.2019.07.004.. (PMID: 31548099) |
| Entry Date(s): | Date Created: 20190923 Date Completed: 20200528 Latest Revision: 20200528 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.cjca.2019.05.035 |
| PMID: | 31542259 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't; Validation Study